Prostate specific antigen (PSA) is the most widely used biomarker for early screening of prostate cancer, contributing to significant decline in prostate cancer (PCa) mortality.1 Despite the benefit, the low specificity of PSA due to its organ-specific rather than cancer-specific nature, can lead to overdiagnosis and overtreatment. The gene discussed is KLK3; the disease is cancer.